Overall rank by patents
#12,252
Across all tracked assignees
USPTO PatentsView assignee record - 25 granted patents across 8 technology areas, active 2017–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
The verdict
TELA holds 25 US patents across 8 technology areas, rank #12,252 of 50,000 tracked assignees.
TELA Bio, Inc. has been granted 25 US utility patents between 2017 and 2025, placing TELA Bio, Inc. at rank #12,252 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.1 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a US Corporation, TELA Bio, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, TELA sits between TECH Friends, Inc. (25 patents, rank #12,248) and Tri-force Management Corporation (25 patents, rank #12,256) - the closest US assignees by grant volume. The composite Innovation Score of 46.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 18 grants, compared with 7 in the 2015–2019 window, a +157% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. TELA Bio, Inc.'s 22.1 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 8 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark TELA Bio, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
TECH FRIENDS, INC.
25 patents
TECHWAY INDUSTRIAL CO., LTD.
25 patents
TEIJIN FRONTIER CO., LTD.
25 patents
TEL FSI, INC.
25 patents
THE HI-TECH ROBOTIC SYSTEMZ LTD
25 patents
THE PARALLAX GROUP INTERNATIONAL, LLC
25 patents
TOTAL RAFFINAGE MARKETING
25 patents
TRI-FORCE MANAGEMENT CORPORATION
25 patents
TELA Bio, Inc.
25 patents
What this shows TELA holds 25 patents at rank #12,252, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #12,252 in granted patent volume.
Other assignees with the most granted patents in TELA's primary technology class.
TELA's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
47 Top 20% higher than 80% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 2 | 8.0% |
| 2018 | 2 | 8.0% |
| 2019 | 3 | 12.0% |
| 2020 | 3 | 12.0% |
| 2022 | 4 | 16.0% |
| 2023 | 2 | 8.0% |
| 2024 | 5 | 20.0% |
| 2025 | 4 | 16.0% |
Top 8 of 8 technology areas
Overall rank by patents
#12,252
Across all tracked assignees
46.7 out of 100
How to use this portfolio
TELA's 25 grants land it in the top 20% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.